KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Enterprise Value (2016 - 2025)

Neogenomics' Enterprise Value history spans 16 years, with the latest figure at -$159.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 58.74% year-over-year to -$159.6 million; the TTM value through Dec 2025 reached -$159.6 million, up 58.74%, while the annual FY2025 figure was -$159.6 million, 58.74% up from the prior year.
  • Enterprise Value reached -$159.6 million in Q4 2025 per NEO's latest filing, up from -$164.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$159.6 million in Q4 2025 to a low of -$802.7 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$415.0 million, with a median of -$412.3 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: plummeted 830.6% in 2021, then surged 58.74% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$515.4 million in 2021, then rose by 15.02% to -$438.0 million in 2022, then rose by 5.2% to -$415.2 million in 2023, then grew by 6.83% to -$386.8 million in 2024, then skyrocketed by 58.74% to -$159.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Enterprise Value are -$159.6 million (Q4 2025), -$164.1 million (Q3 2025), and -$163.7 million (Q2 2025).